Bio News
AstraZeneca’s (AZ) share price fell more than 8% amid reports of a potential merger with Bristol Myers Squibb (BMS), wiping out approximately 33 trillion won in market value. The combined company would have an enterprise value of approximately 600 trillion won, but the market response has been negative. Questions have been raised about the rationale for the merger, as AZ is targeting $80 billion in revenue by 2030.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
